Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis

Epilepsia

Volumn 45, Issue 8, 2004, Pages 924-927

  Ijiri, Yoshio ^a   Inoue, Toru ^b   Fukuda, Furnio ^b   Suzuki, Kaoru ^a   Kobayashi, Toyohide ^a   Shibahara, Nobuhisa ^b   Takenaka, Hiroshi ^a   Tanaka, Kazuhiko ^b  

^a OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Dialyzability; Dialyzer clearance; Hemodialysis; Protein binding rate; Zonisamide

Indexed keywords

FAMOTIDINE; PREDNISOLONE; RANITIDINE; ZONISAMIDE;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; BINDING AFFINITY; BLOOD SAMPLING; CALIBRATION; CASE REPORT; DIALYSATE LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG PROTEIN BINDING; EPILEPSY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; PLASMA CLEARANCE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTICONVULSANTS; ANURIA; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; ISOXAZOLES; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PROTEIN BINDING; RENAL DIALYSIS; SEIZURES;

EID: 4043051650     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2004.30603.x     Document Type: Article

References (12)

1. Ito T, Hori M, Masuda Y, et al. 3-Sulfamoylmethyl-1, 2-benzisoxazole, a new type of anticonvulsant drug: electroencephalographic profile, Arzneimittelorsch Drug Res 1980;30:603-9.
2. Ito T, Yamaguchi T, Miyazaki H, et al. Pharamacokinetic studies of AD-810, a new antiepileptic compound. Arzneimittelorsch Drug Res 1982;32:1581-6.
3. Matsumoto K, Miyazaki H, Fujii T, et al. Absorption, distribution, excretion of 3-(sulfamoylmethyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men. Arzneimittelorsch/Drug Res 1983;33:961-8.
4. Wilensky AJ, Friel PN, Ojemann LM, et al. Zonisamide in epilepsy: a pilot study. Epilepsia 1985;26:212-20.
5. Yagi K, Seono M, Mihara T, et al. Open clinical trial of antiepileptic drug, Zonisamide (ZNA), in 49 patients with refractory epileptic seizures, Seishinigaku 1987;29:111-9.
6. Taylor CP, McLean JR, Brockbrader HN, et al. Zonisamide (AD810, CI-912). In: Meldrum BS, Porter R, eds, Anticonvulsants drugs. London: John Libbey, 1986:277-94.
7. Peters HD, Sorkin EM. Zonisamide: A review of its pharmacokinetic and pharmacodynamic properties, and therapeutic potential in epilepsy. Drugs 1993;45:760-87.
8. Noguchi H, Tomita N, Yoshida K, et al. Simultaneous HPLC determination of Zonisamide and other antiepileptic drugs in human serum [in Japanese]. Yakuri to Chiryo 1988;16:4805-11.
9. Ijiri Y, Ohi K, Suzuki K, et al. Clinical pharmacokinetics of Zonisamide and drug interaction with other anticonvulsants [in Japanese]. Jpn J Hosp Pharm 1994;20:207-12.
10. Ijiri Y, Kobayashi T, Suzuki K, et al. Detection of cis-10, 11-dihydro-10, 11-dihydroxy carbamazepine, an epoxide-diol metabolite in human plasma by high performance liquid chromatography. J Appl Ther Res 1999;12:281-9.
11. Lee CS, Marbury TC. Drug therapy in patients undergoing haemodialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet 1984;9:42-66.
12. Ohmori S, Nakasa H, Asanome K, et al. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta 1998;1380:297-304.